ArticleCureus2026
Lupus-Associated Acute Pancreatitis: A Rare Manifestation of Disease Activity.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pancreatitis affects fewer than 1% of patients with systemic lupus erythematosus (SLE) and usually occurs during active disease. Azathioprine and corticosteroids, both used to treat SLE, can also cause pancreatitis, so the origin of an episode often remains uncertain. A 41-year-old woman with a two-year history of SLE presented in August 2024 with four days of epigastric pain, diarrhea, and migratory polyarthralgia. She had stopped azathioprine on her own and took hydroxychloroquine and prednisone irregularly. Lipase was 17 times the upper limit of normal, and contrast-enhanced computed tomography showed interstitial oedematous pancreatitis with a CT Severity Index of 2. The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) score was 20, with low complement, positive anti-dsDNA, and proteinuria at 0.81 g/L. Gallstones, alcohol, hypertriglyceridemia, hypercalcemia, and drug toxicity were excluded. Pain resolved within 48 hours of three pulses of intravenous methylprednisolone, and CRP fell from 49 to 15 mg/L at one month. Azathioprine had been discontinued before the episode and was subsequently reintroduced without recurrence over 18 months, arguing against drug-induced pancreatitis. In most reported cases, the suspected agent is continued throughout, so this distinction remains unresolved. The exposure sequence observed here supports attributing the episode to lupus activity and favours intensification of immunosuppression over its withdrawal when SLE is active, and no alternative cause is identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.